For example, in the NCT02496208 phase I trial, cabozantinib, a tyrosine kinase inhibitor targeting mainly VEGFR and c-MET, is being evaluated in combination with nivolumab +/− ipilimumab in different genitourinary cancers, including mUC. This evidence concerns the gene MET and urogenital neoplasm.